Indian stocks: Visit www.stage2stocks.com →

NewAmsterdam Pharma Company N.V.

Stage 4 · Declining · week 12

As of Oct 22, 2026, NewAmsterdam Pharma is in Stage 4, the downtrend phase, now in week 12 (since Jul 30, 2026). It closed at $21.58, 47.9% below its 52-week high and below its 200-day average, which is falling.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. More about the company

$21.58
+0.33% today
$2.5B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NAMS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 17w
S2 17w
S3 15w
S2 22w
S3 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 17w → S1 5w → S2 17w → S3 15w → S4 8w → S1 5w → S2 10w → S3 10w → S4 2w → S3 1w → S4 7w → S1 6w → S2 22w → S3 14w → S2 1w → S3 1w → S4 2w → S2 3w → S1 1w → S4 3w → S1 2w → S4 12w current
Total tracked: 165 weeks across 22 stage runs.

NAMS among Biotechnology321st of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…321NAMSStage 4 · wk 1228−4.9%
vs 52W High
-47.9%
$19.83 lo$41.45 hi
47.9% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 12
1w13w26w
Week 12, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-28.6%
200 DMA: $30.20 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
1.16x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-4.9%
3M
-27.2%
6M
-31.4%
YTD
-38.7%
1Y
-40.8%
Scan Membership
Breakout Watch
Latest: 2024-12-02
4 appearances in last 60 days. First seen: 2022-03-08.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 12 · Vol 1.16x
2026-10-21S4
Wk 12 · Vol 0.76x
2026-10-20S4
Wk 12 · Vol 0.73x
2026-10-19S4
Wk 12 · Vol 0.49x
2026-10-16S4
Wk 12 · Vol 1.31x
2026-10-15S4
Wk 11 · Vol 0.59x
2026-10-14S4
Wk 11 · Vol 1.48x
2026-10-13S4
Wk 11 · Vol 0.67x
2026-10-12S4
Wk 11 · Vol 0.55x
2026-10-09S4
Wk 11 · Vol 0.86x
2026-10-08S4
Wk 10 · Vol 1.14x
2026-10-07S4
Wk 10 · Vol 0.95x
Moving averages & range
50 DMA
$23.71
200 DMA
$30.20
52W High
$41.45
52W Low
$19.83
5D Low
$19.83
Resistance levels (recent highs)
20d High
$24.32
60d High
$28.53
120d High
$39.59
250d High
$41.45
Next resistance
+12.7%
to 20d High
ROE
-36.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 4.0

NewAmsterdam Pharma: quick answers

What stage is NewAmsterdam Pharma in?

As of Oct 22, 2026, NewAmsterdam Pharma (NAMS) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 30, 2026 and is in week 12. What the four stages mean

Is NewAmsterdam Pharma in an uptrend?

No. NewAmsterdam Pharma is in a Stage 4 downtrend. It trades 28.6% below its 200-day average, which is falling.

How far is NewAmsterdam Pharma from its 52-week high?

NewAmsterdam Pharma closed at $21.58 on Oct 22, 2026, 47.9% below its 52-week high of $41.45. Its 52-week low is $19.83.

How has NewAmsterdam Pharma performed over the past year?

As of Oct 22, 2026, NewAmsterdam Pharma is down 40.8% over the past year and down 38.7% so far in 2026.

Which sector and industry is NewAmsterdam Pharma in?

NewAmsterdam Pharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.